Patent application number | Description | Published |
20090203537 | NUCLEAR RECEPTOR ASSAY - The present invention relates to methods for measuring compound efficacy and potency on nuclear receptor-co-regulator interaction, comprising the steps of (a) co-incubating at least one nuclear receptor and at least one compound under conditions that allow interaction; (b) co-incubating the nuclear receptor-compound mixture of step (a) with an array of co-regulators, under conditions that allow compound modulated receptor-co-regulator interaction; (c) determination of compound-modulated receptor-co-regulator interaction in function B of co-regulator concentration, and (d) determination of compound-modulated receptor-co-regulator interaction in function of compound concentration; wherein steps (c) and (d) are performed in a single assay. | 08-13-2009 |
20100203043 | TREATMENT AND DIAGNOSIS OF METASTATIC PROSTATE CANCER WITH INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) - The present invention relates to a method for the treatment, prevention and/or diagnosis of metastatic prostate cancer. More specifically inhibitors of Epidermal Growth Factor Receptor (EGFR) are used in the preparation of a pharmaceutical composition for treating or preventing metastatic prostate cancer. The EGFR inhibitors can for instance be EGFR inhibitors, EGFR signaling inhibitors and/or inhibitors of kinases downstream of EGFR kinases. The EGFR inhibitors can also be used in detection, screening, prediction and treatment monitoring methods for metastatic prostate cancer. | 08-12-2010 |
20110111980 | METHOD FOR PROFILING DRUG COMPOUNDS - The present invention relates to systems and methods for testing kinase inhibition using an array of substrates, in particular protein kinase substrates, preferably immobilized on a porous matrix. More particularly, the method provides kinase inhibition profiles of kinase inhibitors using phosphorylation patterns. The present invention can therefore be used to predict the response of cells, tissues, organs and/or warm-blooded animals to a drug, to determine the clinical outcome of a drug therapy and for diagnostical and prognostical purposes. | 05-12-2011 |
20120021939 | METHOD FOR PROFILING DRUG COMPOUNDS USING PROTEIN KINASE INHIBITORS - The present invention relates to a method for determining the effect of a drug on the kinase activity in a sample or predicting the response of a patient to a drug, wherein the kinase activity of a sample in the presence of a protein kinase inhibitor is measured, said protein kinase inhibitor mimicking the effect of said drug compound on the kinase activity in said sample. | 01-26-2012 |
20120046199 | METHOD FOR DETERMINING THE ESTROGEN RECEPTOR STATUS OF BREAST CANCER - The present invention relates to a method for determining the estrogen receptor status of patients suffering from breast cancer. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with breast cancer to specific medicaments. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples obtained from patients diagnosed with breast cancer. | 02-23-2012 |
20120115754 | METHOD FOR DIAGNOSING AND/OR TYPING RENAL CELL CARCINOMA - The present invention relates to a method for diagnosing, typing and/or subtyping renal cell carcinoma as well as predicting the response to medication of patients suffering from renal cell carcinoma. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples of said patients. | 05-10-2012 |
20120135888 | METHOD FOR PREDICTING THE RESPONSE OF LOCALLY ADVANCED RECTAL CANCER TO CHEMORADIOTHERAPY - The present invention relates to a method for determining or predicting the response of a patient diagnosed with locally advanced rectal cancer to chemoradiotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with rectal cancer to specific medicaments, radiotherapy and/or chemotherapy. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples of said patients. | 05-31-2012 |
20130017963 | METHOD FOR DETERMINING SURIVIVAL PROGNOSIS OF PATIENTS SUFFERING FROM NON-SMALL CELL LUNG CANCER (NSCLC)AANM De Wijn; RichardAACI NijmegenAACO NLAAGP De Wijn; Richard Nijmegen NLAANM Ruijtenbeek; RobbyAACI UtrechtAACO NLAAGP Ruijtenbeek; Robby Utrecht NLAANM Hilhorst; Maria HelenaAACI WageningenAACO NLAAGP Hilhorst; Maria Helena Wageningen NL - The present invention relates to a method for determining the survival prognosis of patients suffering from non-small cell lung cancer. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels in response to a kinase inhibitor and profiles in samples obtained from patients diagnosed with non-small cell lung cancer. The present invention also provides methods for predicting the response of a patient diagnosed with non-small cell lung cancer to a medicament. | 01-17-2013 |
20130217055 | METHOD FOR PREDICTING TYROSINE KINASE INHIBITOR (TKI) RESISTANCE IN PATIENTS SUFFERING FROM CHRONIC MYELOGENOUS LEUKEMIA (CML) - The present invention relates to a method for determining or predicting the response of a patient diagnosed with chronic myelogenous leukaemia (CML) to treatment with a tyrosine kinase inhibitor. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles and inhibitions thereof thereby diagnosing CML patients resistant to treatment with Imatinib. | 08-22-2013 |
20140155286 | MODIFIED TYROSINE AMINO ACIDS, PEPTIDES CONTAINING THEM, AND THEIR USE FOR DETECTING HYDROLASE ENZYME ACTIVITY - The present invention relates to a method and tools which allow the kinetic monitoring of hydrolase enzyme activity. The present invention also aims to provide synthetic peptides and peptide residues modified such that they can be used in assays for monitoring hydrolase enzyme activity, and preferably phosphatase activity. Also claimed are modified tyrosine amino acid derivatives of formula (IV), wherein Y is chosen from —PO | 06-05-2014 |